CollPlant Biotechnologies, a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drug candidates with more effective, human-relevant methods.
Importantly, CollPlant's Collink.3D® portfolio of rhCollagen-based BioInk products can be utilized for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems, which serve as alternatives to animal testing. These systems can expedite the gap between benchtop studies and clinical trials, as well as be more economical and enable a reduced time to market.
Yehiel Tal, CollPlant's Chief Executive Officer, commented, "The FDA's new approach to develop alternatives for use in place of traditional animal testing, often referred to as 'New Approach Methodologies', or NAMs, is designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation, lowering research and development costs, and ultimately, drug prices. CollPlant's novel rhCollagen-based Collink.3D portfolio of BioInk products supports the FDA's NAMs since they can be used in a wide variety of non-animal testing applications. For example, CollPlant's BioInk products are ideal for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems used for drug discovery and regenerative medicine applications and are designed to be compatible with in-vitro human-based systems like organoids. We anticipate that our BioInks will be instrumental to enable alternatives for achieving the goal of phasing out animal testing in five years."
Mr. Tal added, "CollPlant has also developed Computational Modeling and Simulation (CM&S) methodologies to assist in the development of its regenerative breast implant product candidate. Mimicry of the implant and human body interaction using CM&S, enables precise prediction of mechanical behavior of the implants in the body, as well as provides information about degradation kinetics, tissue remodeling and interaction with the host tissue. These smart tools are reducing the need for animal studies and are accelerating the development of safer and more effective human-specific solutions. The same development tools can be applied to any other soft or hard tissue type to optimize the development of regenerative implants."
About Collink.3D BioInk:
CollPlant's Collink.3D BioInk pipeline consists of the first and only line of human collagen BioInk products based on chemically modified plant-derived rhCollagen that is mass-produced with high purity and consistency.
About CollPlant:
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
